Researchers develop a novel method to screen publicly available raw WGS data of SARS-CoV-2
In a recent study posted to the bioRxiv* preprint server, researchers developed a novel method to screen publically available raw whole genome sequencing (WGS) data of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and...
UBC researchers discover ‘weak spot’ across major COVID-19 variants
Researchers at the University of British Columbia have discovered a key vulnerability across all major variants of the SARS-CoV-2 virus, including the recently emerged BA.1 and BA.2 Omicron subvariants.
Credit: Dr. Sriram Subramaniam, UBC
Researchers at...
Molecular Assemblies Is Enzymatically Synthesizing the Next Generation of DNA Products
Molecular Assemblies’ enzymatic approach is based on how nature makes DNA—in water—to overcome the length, purity, and accuracy limitations of the chemical DNA synthesis method. The technology by Molecular Assemblies employs a template-independent DNA...
UNITY Biotechnology Announces Pricing of Upsized Underwritten Public Offering – GlobeNewswire
SOUTH SAN FRANCISCO, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) (Nasdaq:UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced the pricing of an...
Acid ceramidase is a SARS-CoV-2 host factor, study says
Fluoxetine, a common antidepressant, inhibits the SARS-CoV-2 coronavirus in cell cultures and in preparations from human lung tissue. This was demonstrated by researchers at Julius-Maximilians-Universität (JMU) Würzburg in the summer of 2020. However, the...
Largest beer brewer to use sustainable PEF bottles – European Biotechnology News
Avantium and AmBev, part of AB InBev Group, have inked an agreement on PEF for soft drink bottles.
The contract is a milestone for industrial biotechnology. Under the agreement, the Brazilian subsidy of the...
New drug candidate uses novel absorption method to target cancer cells in mice
A team of University of Michigan researchers is developing a new anti-cancer drug that is absorbed through the gut’s lymphatic system rather than blood vessels, potentially outmaneuvering the molecular signaling pathways that lead to...
Transcription Factors Driving CAR T Cell Dysfunction
Broadcast Date: September 9, 2022Time: 9:00 am PT, 12:00 pm ET, 18:00 CET
REGISTER NOW
Chimeric antigen receptor (CAR) T cell therapy has achieved remarkable success in hematological malignancies. Yet, it remains ineffective in solid...
Australian company accelerating the speed of drug discovery wins prestigious Eureka prize
21 October 2021 — Inventia Life Science, a Sydney-based biotechnology company, announced that its RASTRUM™ 3D cell culture platform, developed in collaboration with researchers from UNSW Chemistry, the Australian Centre for NanoMedicine and the...
Inventia Life Science partners with Xylyx Bio to develop tissue-specific, digitally-printed bioinks for drug...
1 September 2021 — Inventia Life Science, a Sydney-based biotechnology company, and Xylyx Bio, a New York-based leader in advanced biomaterials, today announced their strategic partnership following promising results developing more realistic, scalable, and...
